The antitumor effect of immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 is higher than that of conventional chemotherapy and is durable, improving the survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Here, CTLA4 is linked to head and neck squamous cell carcinoma.